Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when
characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Background Evidence from retrospective studies suggests that disease progression after first-
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer
(NSCLC) sites of gross disease at presentation are the first to progress when treated with …

Importance The oligometastatic paradigm postulates that patients with a limited number of
metastases can be treated with ablative local therapy to each site of disease with curative …

Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …

Objectives: Common origins for brain metastases (BMs) are melanoma, lung, breast, and
renal cell cancers. BMs account for a large share of morbidity and mortality caused by these …

Background and purpose Both stereotactic radiotherapy (SRT) and immune-or targeted
therapy play an increasingly important role in personalized treatment of metastatic disease …

17. When managing NSGCTs, PM is indicated for select patients with limited number of lung
abnormalities after first-line or second-line platin-based chemotherapy suspected of …